Thermo King’s Truck Hybrid Refrigeration Units Hit the Roads
Thermo King®, a leader in transport temperature control solutions and a brand of Trane Technologies (NYSE: TT), today announced that its new hybrid refrigeration systems for trucks and high-loaders are being delivered to customers across Europe. The new T-Series Hybrid and UT Hybrid refrigeration systems seamlessly switch between diesel and electric mode allowing transporters to operate in inner cities, residential areas and low emission zones with the unit’s diesel engine turned off.
Greggs, UK’s leading bakery food-on-the-go retailer with over 1,800 shops nationwide and serving over six million customers a week, is one of the first customers in Europe to experience the benefits of the new hybrid refrigeration systems. Three new trucks with Thermo King’s hybrid systems will contribute to lowering the environmental impact and reducing operating costs of their truck transport operations in central London.
“Thermo King units have been our systems of choice for several years now. Their units have delivered good flexibility and work efficiency to our operations, and we could also always count on the Thermo King dealer service network to support us,” said Richard Penna, group logistics manager at Greggs. “We’re very cautious about the sustainability of our transport operations. It is paramount for us to operate in inner cities with as little noise and reduced emissions as possible. It was a natural choice to work with Thermo King and equip our trucks with these new units that can easily switch from diesel operation to electric, reduce the sound level and eliminate emissions. On top of that, we expect to benefit from the lower daily fuel consumption.”
“Thermo King Hybrid technology was designed to help transport and delivery companies future-proof their refrigerated operations and investments. With this solution they can stay ahead of regulations, control their total cost of ownership and achieve important sustainability goals,” said Colm O’Grady, product manager at Thermo King. “Thermo King was the first to offer its European customers a trailer hybrid refrigeration. Now, our truck transport customers can also benefit from this cleaner and electrified transport refrigeration to make urban distribution more flexible and sustainable.”
The new hybrid single- and multi-temperature solution for trucks feature Frigoblock alternator and inverter-drive technology. The nose-mount T-Series Hybrid and under-mount UT Hybrid refrigeration automatically switches between electric and diesel operation as required or necessary. This enables the transport companies to operate in inner cities, residential areas and low emission zones with the refrigeration unit’s diesel engine turned off.
The system is also well accepted by drivers, mainly due to the simple and smooth transition from one drive technology to the other. The driver only needs to set the vehicle when leaving the depot and the system will switch electric and diesel modes seamlessly during the working day depending on the unit’s requirements.
The T-Series Hybrid and UT Hybrid solutions are aligned with Trane Technologies’ 2030 sustainability commitments, and the commitment to reduce customers’ carbon emissions by one gigaton – equivalent to the annual emissions of Italy, France and the United Kingdom combined.
About Thermo King
Thermo King is a brand of Trane Technologies (NYSE: TT), a global climate innovator, and a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers and railway cars since 1938. For more information, visit www.europe.thermoking.com or www.tranetechnologies.com.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our portfolio of environmentally responsible products and services, we bring efficient and sustainable climate solutions to buildings, homes and transportation. For more information, please visit tranetechnologies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200719005017/en/
Contact information
Media:
Geraldine Velner, Trane Technologies
+353-85-704-6944
Geraldine.velner@tranetechnologies.com
Investors:
Zachary Nagle, Trane Technologies
+1-704-990-3913
Zachary.nagle@tranetechnologies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom